American Society of Clinical Oncology

The American Society of Clinical Oncology (ASCO) is the world's leading professional organization representing physicians of all oncology subspecialties who care for people with cancer.[citation needed] Founded in 1964 by Drs. Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane Wright, ASCO's more than 27,000 members from the United States and abroad set the standard for patient care worldwide.[citation needed] ASCO members lead the fight for more effective cancer treatments, increased funding for clinical and translational research, and, ultimately, cures for the many different types of cancer that strike an estimated 10 million people worldwide each year.[citation needed]

Source: Wikipedia

Lobbying

$128,859 Spent
Information

Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.

For more information, please see our lobbying methodology page.

covers through Q3, 2011

Lobbying On Behalf of American Society of Clinical Oncology

View all lobbying data for American Society of Clinical Oncology Sources: Lobbyist Registration Tracker OpenSecrets.org

Regulations

9 Mentions
Information

All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.

Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.

Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.

Regulations and public comments can be downloaded in bulk here.

updated from Regulations.gov on September 27, 2011

The tables show occurrences of "American Society of Clinical Oncology" in public comments on proposed federal regulations.

  • Mentions in Document Text
    • Mentions
    • Agency
    • Docket
    • Date
    • Toggle 2 CMS Changes to the Electronic Prescribing (eRx) Incentive Program 2011
    • Toggle 1 CDC Assessing the Current Research, Policy, and Practice Environment in Public Health Genomics 2011
    • Toggle 1 CMS FY 2012 Changes to the Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long Term Care Hospital Prospective Payment System and FY 2012 Rates 2011
    • Toggle 1 CMS Hospital Outpatient Prospective Payment; Ambulatory Surgical Center Payment; Hospital Value-Based Purchasing Program; Physician Self-Referral; and Provider Agreement Regulations on Patient Notification Requirements 2011
    • Toggle 1 DOJ Preliminary Plan for Retrospective Analysis of Existing Rules 2011
    • Toggle 1 CMS Methods for Assuring Access to Covered Medicaid Services (CMS-2328-P) 2011
    • Toggle 1 FDA Draft Guidance for Industry and FDA Staff: Commercially Distributed In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only: Frequently Asked Questions; Availability 2011
    • Toggle 1 FDA Draft Guidance for Industry on Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics; Availability 2011
    • Toggle 1 FDA Ventana Medical Systems, Inc., Premarket Approval for INFORM® HER2 Dual ISH DNA Probe Cocktail P100027, Approved 6/14/11 2011

Advisory Committees

2 people on 2 committees
Information

Data is based on disclosures required by the Federal Advisory Committee Act (FACA). Matches are based on the occurrence of the company name in the committee member affiliation. Variations in company names may cause some matches to be missed.

The table shows only the top 10 agencies. To search and download raw records from the complete dataset see the FACA data section.

covers through 2011

Table shows employees of "American Society of Clinical Oncology" that sat on federal advisory committees.

  • Agency
  • Representation
  • Toggle Corporation for National and Community Service 1 person on 1 committee
  • Toggle Department of Health and Human Services 1 person on 1 committee
View all advisory committee data for American Society of Clinical Oncology